Bi-level Positive Airway Pressure Devices (BiPAP) Market - 2024-2033

February 2026 | 186 pages | ID: B3F6C4A84900EN
DataM Intelligence

Abstracts

The Bi-level Positive Airway Pressure Devices (BiPAP) Market was valued at US$ 1.45 Billion in 2024 and is anticipated to reach US$ 3.70 Billion by 2033, at a CAGR of 0.055 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Bi-level Positive Airway Pressure Devices (BiPAP) Market.

This report delivers a comprehensive overview of the Bi-level Positive Airway Pressure Devices (BiPAP) Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Bi-level Positive Airway Pressure Devices (BiPAP) Market. The Bi-level Positive Airway Pressure Devices (BiPAP) Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

Bi-level Positive Airway Pressure Devices (BiPAP) Market Scope:

By Product

• Devices
• Masks
• Aftermarket Parts and Accessories

By Indication

• Obstructive Sleep Apnea
• Central Sleep Apnea
• Complex Sleep Apnea
• Chronic Obstructive Pulmonary Disease (COPD)
• Acute Respiratory Failure
• Chronic Respiratory Failure
• Neuromuscular Disorders
• Obesity Hypoventilation Syndrome
• Pneumonia and Other Respiratory Infections
• Post-operative Respiratory Support
• Others

By Technology

• Integrated Humidification
• Heated Tubing
• Smart Connectivity
• Bluetooth-enabled Devices
• Wi-Fi-enabled Devices
• Cloud-based Monitoring
• Telemonitoring Compatible Devices
• Noise Reduction Technology
• Pressure Relief Technology
• Leak Compensation Systems
• Touchscreen / Digital Interface
• Others

By Portability

• Stationary Devices
• Portable Devices
• Travel-friendly Devices
• Others

By Patient Type

• Adult
• Pediatric
• Geriatric

By End-User

• Hospitals
• Academic / Teaching Hospitals
• Sleep Clinics and Sleep Laboratories
• Home Healthcare Settings
• Ambulatory Surgical Centers
• Long-term Care Facilities
• Rehabilitation Centers
• Others

Key Players

• Pfizer, Inc.
• Otsuka Pharmaceutical Co., Ltd.
• GlaxoSmithKline plc
• H. Lundbeck A/S
• Johnson & Johnson
• Bristol-Myers Squibb Company
• BioXcel Therapeutics, Inc.
• Impel Pharmaceuticals Inc.
• Lee Pharma Limited
• Teva Pharmaceutical Industries Ltd.
• Amneal Pharmaceuticals LLC
• AbbVie Inc.
• Aurobindo Pharma Limited
• Apotex Inc.
• F. Hoffmann-La Roche Ltd.
• Hikma Pharmaceuticals PLC
• Axsome Therapeutics, Inc.
• Alkermes plc
• Alexza Pharmaceuticals, Inc.

Major Highlights

This report delivers a comprehensive overview of the Bi-level Positive Airway Pressure Devices (BiPAP) Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Bi-level Positive Airway Pressure Devices (BiPAP) Market. The Bi-level Positive Airway Pressure Devices (BiPAP) Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

• North America (U.S., Canada, Mexico)
• Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
• Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
• South America (Colombia, Brazil, Argentina, Rest of South America)
• Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

• Increase Your Customer Base by 3X using our Partner Identification tool
• Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
• Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
• Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Contents

1. DEFINITION AND OVERVIEW

1.1. Study Objectives
1.2. Market Definition
1.3. Market Scope
1.4. Stakeholder Analysis
1.5. Currency Considered
1.6. Study Period

2. EXECUTIVE SUMMARY

2.1. Key Takeaways
2.2. Top To Bottom Analysis
2.3. Market Share Analysis
2.4. Data Points from Key Primary Interviews
2.5. Data Points from Key Secondary Databases
2.6. Market Snapshot
2.7. Geographical Snapshot

3. DYNAMICS

3.1. Impacting Factors
  3.1.1. Drivers
    3.1.1.1. Rising prevalence of psychiatric disorders and substance-induced agitation
    3.1.1.2. Increasing emergency department visits related to acute behavioral disturbances
    3.1.1.3. Growing adoption of rapid-acting and novel drug delivery formulations
  3.1.2. Restraints
    3.1.2.1. Safety concerns and adverse effects associated with antipsychotics and sedatives
    3.1.2.2. Stringent regulatory scrutiny and post-marketing safety requirements
  3.1.3. Opportunity
    3.1.3.1. Development of non-invasive and fast-acting delivery systems (inhaled, intranasal, sublingual)
    3.1.3.2. Increasing demand in emerging markets due to improving psychiatric care access
    3.1.3.3. Pipeline development targeting agitation in dementia and Alzheimer’s disease
  3.1.4. Trends
    3.1.4.1. Shift toward atypical antipsychotics with improved safety profiles
    3.1.4.2. Increasing preference for rapid-onset formulations in emergency psychiatry
  3.1.5. Impact Analysis

4. INDUSTRY ANALYSIS

4.1. Porter’s Five Force Analysis – Global Bi-level Positive Airway Pressure Devices (BiPAP)
4.2. Geopolitical & Supply Chain Exposure
  4.2.1. API Sourcing Concentration for Antipsychotics and Benzodiazepines
  4.2.2. Trade Policies, Export Controls, and Psychiatric Drug Supply Risks
4.3. Social & Patient-Centric Factors
  4.3.1. Physician Prescribing Behavior in Emergency Psychiatry and Acute Care
  4.3.2. Brand Preference vs Generic Substitution Across Antipsychotics and Sedatives
  4.3.3. Patient and Caregiver Concerns Regarding Sedation, Safety, and Monitoring
  4.3.4. Awareness Gaps in Early Recognition and Management of Acute Agitation
4.4. Economic Factors
  4.4.1. Reimbursement and Coverage in Hospital and Emergency Care Settings
  4.4.2. Inflationary Pressure on APIs, Sterile Injectables, and CNS Drug Manufacturing
  4.4.3. Currency Volatility Impacting Export-Oriented CNS Drug Manufacturers
4.5. Pricing Analysis
4.6. Regulatory Analysis
4.7. Go-To-Market (GTM) Strategy
4.8. Innovation & R&D Trends
4.9. Sustainability and ESG Analysis
4.10. Acute Agitation Treatment Ecosystem Participants
4.11. Buyer Decision Criteria & Adoption Drivers
4.12. DMI Opinion – Strategic Outlook for the Global Bi-level Positive Airway Pressure Devices (BiPAP) Market

5. BY PRODUCT

5.1. Introduction
  5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  5.1.2. Market Attractiveness Index, By Product
5.2. Devices*
  5.2.1. Introduction
  5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  5.2.3. Fixed Pressure BiPAP Devices
  5.2.4. Auto-adjusting BiPAP Devices
  5.2.5. BiPAP ST (Spontaneous/Timed) Devices
  5.2.6. BiPAP AVAPS Devices
  5.2.7. Portable / Travel BiPAP Devices
  5.2.8. ICU / Critical Care BiPAP Systems
  5.2.9. Pediatric / Neonatal BiPAP Devices
  5.2.10. Others
5.3. Masks
  5.3.1. Full Face Masks
  5.3.2. Nasal Masks
  5.3.3. Nasal Pillow Masks
  5.3.4. Total Face Masks
  5.3.5. Pediatric Masks
  5.3.6. Others
5.4. Aftermarket Parts and Accessories
  5.4.1. Tubing / Breathing Circuits
  5.4.2. Humidifiers
  5.4.3. Filters
  5.4.4. Headgear and Straps
  5.4.5. Cushions and Mask Liners
  5.4.6. Water Chambers
  5.4.7. Batteries and Power Adapters
  5.4.8. Carrying Cases
  5.4.9. Others

6. BY INDICATION

6.1. Introduction
  6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  6.1.2. Market Attractiveness Index, By Indication
6.2. Obstructive Sleep Apnea*
  6.2.1. Introduction
  6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Central Sleep Apnea
6.4. Complex Sleep Apnea
6.5. Chronic Obstructive Pulmonary Disease (COPD)
6.6. Acute Respiratory Failure
6.7. Chronic Respiratory Failure
6.8. Neuromuscular Disorders
6.9. Obesity Hypoventilation Syndrome
6.10. Pneumonia and Other Respiratory Infections
6.11. Post-operative Respiratory Support
6.12. Others

7. BY TECHNOLOGY

7.1. Introduction
  7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  7.1.2. Market Attractiveness Index, By Technology
7.2. Integrated Humidification*
  7.2.1. Introduction
  7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Heated Tubing
7.4. Smart Connectivity
7.5. Bluetooth-enabled Devices
7.6. Wi-Fi-enabled Devices
7.7. Cloud-based Monitoring
7.8. Telemonitoring Compatible Devices
7.9. Noise Reduction Technology
7.10. Pressure Relief Technology
7.11. Leak Compensation Systems
7.12. Touchscreen / Digital Interface
7.13. Others

8. BY PORTABILITY

8.1. Introduction
  8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Portability
  8.1.2. Market Attractiveness Index, By Portability
8.2. Stationary Devices*
  8.2.1. Introduction
  8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Portable Devices
8.4. Travel-friendly Devices
8.5. Others

9. BY PATIENT TYPE

9.1. Introduction
  9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
  9.1.2. Market Attractiveness Index, By Patient Type
9.2. Adult*
  9.2.1. Introduction
  9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Pediatric
9.4. Geriatric

10. BY END-USER

10.1. Introduction
  10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  10.1.2. Market Attractiveness Index, By End-User
10.2. Hospitals*
  10.2.1. Introduction
  10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Academic / Teaching Hospitals
10.4. Sleep Clinics and Sleep Laboratories
10.5. Home Healthcare Settings
10.6. Ambulatory Surgical Centers
10.7. Long-term Care Facilities
10.8. Rehabilitation Centers
10.9. Others

11. BY REGION

11.1. Introduction
  11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  11.1.2. Market Attractiveness Index, By Region
11.2. North America
  11.2.1. Introduction
  11.2.2. Key Region-Specific Dynamics
  11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Portability
  11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
  11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  11.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.2.9.1. US
    11.2.9.2. Canada
    11.2.9.3. Mexico
11.3. Europe
  11.3.1. Introduction
  11.3.2. Key Region-Specific Dynamics
  11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Portability
  11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
  11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  11.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.3.9.1. Germany
    11.3.9.2. UK
    11.3.9.3. France
    11.3.9.4. Russia
    11.3.9.5. Italy
    11.3.9.6. Spain
    11.3.9.7. Norway
    11.3.9.8. Netherlands
    11.3.9.9. Sweden
    11.3.9.10. Denmark
    11.3.9.11. Belgium
    11.3.9.12. Switzerland
    11.3.9.13. Austria
    11.3.9.14. Poland
    11.3.9.15. Finland
    11.3.9.16. Rest of Europe
11.4. Latin America
  11.4.1. Introduction
  11.4.2. Key Region-Specific Dynamics
  11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Portability
  11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
  11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  11.4.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.4.9.1. Brazil
    11.4.9.2. Argentina
    11.4.9.3. Rest of Latin America
11.5. Asia-Pacific
  11.5.1. Introduction
  11.5.2. Key Region-Specific Dynamics
  11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Portability
  11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
  11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  11.5.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.5.9.1. China
    11.5.9.2. India
    11.5.9.3. Japan
    11.5.9.4. Australia
    11.5.9.5. South Korea
    11.5.9.6. New Zealand
    11.5.9.7. Indonesia
    11.5.9.8. Malaysia
    11.5.9.9. Philippines
    11.5.9.10. Singapore
    11.5.9.11. Thailand
    11.5.9.12. Vietnam
    11.5.9.13. Rest of Asia-Pacific
11.6. Middle East and Africa
  11.6.1. Introduction
  11.6.2. Key Region-Specific Dynamics
  11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Portability
  11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
  11.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  11.6.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.6.9.1. UAE
    11.6.9.2. Saudi Arabia
    11.6.9.3. South Africa
    11.6.9.4. Israel
    11.6.9.5. Egypt
    11.6.9.6. Turkey
    11.6.9.7. Qatar
    11.6.9.8. Kuwait
    11.6.9.9. Oman
    11.6.9.10. Bahrain
    11.6.9.11. Rest of Middle East and Africa

12. COMPETITIVE LANDSCAPE ANALYSIS

12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
12.4. Partner Identification Analysis
12.5. Investment & Funding Landscape
12.6. Strategic Alliances & Innovation Pipelines

13. COMPANY PROFILES

13.1. Pfizer, Inc.*
  13.1.1. Company Overview
  13.1.2. Product Portfolio
  13.1.3. Revenue Analysis
  13.1.4. Pricing Analysis
  13.1.5. SWOT Analysis
  13.1.6. Recent Developments
    13.1.6.1. Major Deals
    13.1.6.2. M&A
    13.1.6.3. Collaboration
    13.1.6.4. Acquisition
    13.1.6.5. Joint Ventures
    13.1.6.6. Innovations
  13.1.7. Recent News
    13.1.7.1. Events
    13.1.7.2. Conferences
    13.1.7.3. Symposiums
    13.1.7.4. Webinars
13.2. Otsuka Pharmaceutical Co., Ltd.
13.3. GlaxoSmithKline plc
13.4. H. Lundbeck A/S
13.5. Johnson & Johnson
13.6. Bristol-Myers Squibb Company
13.7. BioXcel Therapeutics, Inc.
13.8. Impel Pharmaceuticals Inc.
13.9. Lee Pharma Limited
13.10. Teva Pharmaceutical Industries Ltd.
13.11. Amneal Pharmaceuticals LLC
13.12. AbbVie Inc.
13.13. Aurobindo Pharma Limited
13.14. Apotex Inc.
13.15. F. Hoffmann-La Roche Ltd.
13.16. Hikma Pharmaceuticals PLC
13.17. Axsome Therapeutics, Inc.
13.18. Alkermes plc
13.19. Alexza Pharmaceuticals, Inc. (LIST NOT EXHAUSTIVE )

14. GLOBAL BI-LEVEL POSITIVE AIRWAY PRESSURE DEVICES (BIPAP) MARKET – RESEARCH METHODOLOGY

14.1. Research Data
  14.1.1. Secondary Data
  14.1.2. Primary Data
  14.1.3. CAGR Analysis
14.2. Market Size Estimation Methodology
  14.2.1. Bottom-Up Approach
  14.2.2. Top-Down Approach
14.3. Market Breakdown & Data Triangulation
14.4. Research Assumptions
14.5. Limitations

15. APPENDIX

15.1. About Us and Services
15.2. Contact Us